BeautyHealth Continues To See FY23 Net sales Of $460M-$480M,Consensus $461.57M; Refines Adjusted EBITDA Margin Outlook From 18%-20% To 18%-19%
Portfolio Pulse from Benzinga Newsdesk
BeautyHealth has refined its FY23 net sales outlook to $460M-$480M, in line with the consensus of $461.57M. The company has also adjusted its EBITDA margin outlook from 18%-20% to 18%-19%.
August 09, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BeautyHealth's refined FY23 net sales and EBITDA margin outlooks are in line with market expectations, which may not significantly impact the stock price.
BeautyHealth's revised FY23 net sales and EBITDA margin outlooks are in line with market expectations. This suggests that the market has already priced in this information, and therefore, it may not have a significant impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100